Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 2
1982 1
1983 1
1984 2
1985 1
1986 3
1988 1
1989 6
1990 3
1991 1
1993 1
1994 5
1995 4
1996 1
1997 5
1998 5
1999 4
2000 3
2001 6
2002 8
2003 6
2004 4
2005 11
2006 4
2007 8
2008 9
2009 9
2010 13
2011 13
2012 14
2013 15
2014 21
2015 20
2016 32
2017 26
2018 30
2019 34
2020 29
2021 40
2022 32
2023 40
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

412 results

Results by year

Filters applied: . Clear all
The following term was ignored: %
Page 1
Bortezomib for the treatment of multiple myeloma.
Scott K, Hayden PJ, Will A, Wheatley K, Coyne I. Scott K, et al. Cochrane Database Syst Rev. 2016 Apr 20;4(4):CD010816. doi: 10.1002/14651858.CD010816.pub2. Cochrane Database Syst Rev. 2016. PMID: 27096326 Free PMC article. Review.
Two trials were published in abstract form and therefore we were unable to assess potential risk of bias in full.There is moderate-quality evidence that bortezomib prolongs OS (four studies, 1586 patients; Peto OR 0.77, 95% CI 0.65 to 0.92) and PFS (five studies, 1855 p …
Two trials were published in abstract form and therefore we were unable to assess potential risk of bias in full.There is moderate-quality e …
Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
Ahmed W, Galati J, Kumar A, Christos PJ, Longman R, Lukin DJ, Scherl E, Battat R. Ahmed W, et al. Clin Gastroenterol Hepatol. 2022 Mar;20(3):e361-e379. doi: 10.1016/j.cgh.2021.03.034. Epub 2021 Mar 31. Clin Gastroenterol Hepatol. 2022. PMID: 33798711 Review.
METHODS: Through a systematic search of multiple electronic databases through November 9, 2020, we identified cohort studies or case series (>10 patients) reporting the safety and effectiveness of simultaneous use of biologic agents in combination or with tofacit …
METHODS: Through a systematic search of multiple electronic databases through November 9, 2020, we identified cohort studies or case …
Safety and management of niraparib monotherapy in ovarian cancer clinical trials.
Monk BJ, González-Martin A, Buckley L, Matulonis UA, Rimel BJ, Wu X, Moore KN, Mirza MR. Monk BJ, et al. Int J Gynecol Cancer. 2023 Jun 5;33(6):971-981. doi: 10.1136/ijgc-2022-004079. Int J Gynecol Cancer. 2023. PMID: 36792166 Free PMC article. Review.
In five trials assessing efficacy of niraparib in patients with advanced epithelial ovarian cancer (PRIMA, NOVA, NORA, QUADRA, and PRIME), treatment-emergent adverse events of any grade were reported in nearly all patients (99%) receiving niraparib; the events were …
In five trials assessing efficacy of niraparib in patients with advanced epithelial ovarian cancer (PRIMA, NOVA, NORA, QUADRA, and PR …
Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials.
Pandy JGP, Franco PIG, Li RK. Pandy JGP, et al. Support Care Cancer. 2022 Nov;30(11):8655-8666. doi: 10.1007/s00520-022-07175-3. Epub 2022 Jun 2. Support Care Cancer. 2022. PMID: 35655045 Review.
This meta-analysis evaluated data from high-quality trials to provide strong evidence in forming recommendations to prevent systemic cancer therapy-induced HFS/HFSR. METHODS: A systematic search of PubMed, Embase, Cochrane, clinical trials databases, and hand searching wer …
This meta-analysis evaluated data from high-quality trials to provide strong evidence in forming recommendations to prevent systemic cancer …
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups.
Batlevi CL, Sha F, Alperovich A, Ni A, Smith K, Ying Z, Soumerai JD, Caron PC, Falchi L, Hamilton A, Hamlin PA, Horwitz SM, Joffe E, Kumar A, Matasar MJ, Moskowitz AJ, Moskowitz CH, Noy A, Owens C, Palomba LM, Straus D, von Keudell G, Zelenetz AD, Seshan VE, Younes A. Batlevi CL, et al. Blood Cancer J. 2020 Jul 17;10(7):74. doi: 10.1038/s41408-020-00340-z. Blood Cancer J. 2020. PMID: 32678074 Free PMC article.
Patients with follicular lymphoma (FL) frequently require multiple treatments during their disease course; however, survival based on lines of treatment remains poorly described in the post-rituximab era. ...The reduced survival we observed after second-line and lat …
Patients with follicular lymphoma (FL) frequently require multiple treatments during their disease course; however, survival b …
Deep Learning Predicts Lung Cancer Treatment Response from Serial Medical Imaging.
Xu Y, Hosny A, Zeleznik R, Parmar C, Coroller T, Franco I, Mak RH, Aerts HJWL. Xu Y, et al. Clin Cancer Res. 2019 Jun 1;25(11):3266-3275. doi: 10.1158/1078-0432.CCR-18-2495. Epub 2019 Apr 22. Clin Cancer Res. 2019. PMID: 31010833 Free PMC article.
Models were developed using transfer learning of convolutional neural networks (CNN) with recurrent neural networks (RNN), using single seed-point tumor localization. Pathologic response validation was performed on dataset B, comprising 89 patients with NSCLC treate …
Models were developed using transfer learning of convolutional neural networks (CNN) with recurrent neural networks (RNN), using single seed …
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.
Leypoldt LB, Tichy D, Besemer B, Hänel M, Raab MS, Mann C, Munder M, Reinhardt HC, Nogai A, Görner M, Ko YD, de Wit M, Salwender H, Scheid C, Graeven U, Peceny R, Staib P, Dieing A, Einsele H, Jauch A, Hundemer M, Zago M, Požek E, Benner A, Bokemeyer C, Goldschmidt H, Weisel KC. Leypoldt LB, et al. J Clin Oncol. 2024 Jan 1;42(1):26-37. doi: 10.1200/JCO.23.01696. Epub 2023 Sep 27. J Clin Oncol. 2024. PMID: 37753960 Free PMC article.
TE patients received high-dose melphalan. TNE patients received two additional Isa-KRd cycles postinduction. ...Eighty-one of 99 TE-ITT-IA patients reached MRD negativity at any time point (81.8%). MRD negativity was sustained for 1 year in 62.6% of patien …
TE patients received high-dose melphalan. TNE patients received two additional Isa-KRd cycles postinduction. ...Eighty-one of …
Immunosurveillance in clinical cancer management.
Kroemer G, Chan TA, Eggermont AMM, Galluzzi L. Kroemer G, et al. CA Cancer J Clin. 2024 Mar-Apr;74(2):187-202. doi: 10.3322/caac.21818. Epub 2023 Oct 25. CA Cancer J Clin. 2024. PMID: 37880100 Free article. Review.
This is true not only for immunotherapies, such as immune checkpoint inhibitors (ICIs), but also for conventional chemotherapy, targeted anticancer agents, and radiation therapy. Thus, therapeutics that stress and kill cancer cells while provoking a tumor-tar …
This is true not only for immunotherapies, such as immune checkpoint inhibitors (ICIs), but also for conventional chemotherapy, targeted ant …
Systemic treatment of HCC in special populations.
Rimassa L, Personeni N, Czauderna C, Foerster F, Galle P. Rimassa L, et al. J Hepatol. 2021 Apr;74(4):931-943. doi: 10.1016/j.jhep.2020.11.026. Epub 2020 Nov 26. J Hepatol. 2021. PMID: 33248171 Review.
While several large phase III trials have provided the evidence for a multi-line treatment paradigm, they have focused on a highly selected group of patients by excluding potentially confounding comorbidities. As a result, high quality evidence for the systemic treatment o …
While several large phase III trials have provided the evidence for a multi-line treatment paradigm, they have focused on a highly selected …
Multiple myeloma, race, insurance and treatment.
Joshi H, Lin S, Fei K, Renteria AS, Jacobs H, Mazumdar M, Jagannath S, Bickell NA. Joshi H, et al. Cancer Epidemiol. 2021 Aug;73:101974. doi: 10.1016/j.canep.2021.101974. Epub 2021 Jul 6. Cancer Epidemiol. 2021. PMID: 34243048 Free PMC article.
We studied patterns of treatment disparities and unplanned interruptions among the MM patients after the Affordable Care Act to assess their prevalence and effect on survival. ...Underuse of maintenance therapy (aOR = 1.98; 95 % CI 1.12-3.48) and interruption …
We studied patterns of treatment disparities and unplanned interruptions among the MM patients after the Affordable Care Act t …
412 results